TY - JOUR
T1 - Endoscopic ultrasonography-guided gastroenterostomy for malignant gastric outlet obstruction
T2 - Comparison between gastric and duodenal obstruction
AU - van de Pavert, Yorick L
AU - Pheifer, Maronne I D
AU - van Leeuwen, Louise W H
AU - Bijlsma, Rina
AU - Bruno, Marco
AU - van Dullemen, Hendrik M
AU - Fockens, Paul
AU - Inderson, Akin
AU - Lammers, Willem J
AU - Venneman, Niels G
AU - Voermans, Rogier P
AU - van Wanrooij, Roy L J
AU - de Wijkerslooth, Thomas R
AU - Moons, Leon M G
AU - Vleggaar, Frank P
N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).
PY - 2026
Y1 - 2026
N2 - BACKGROUND AND STUDY AIMS: It is currently unclear whether obstruction location affects clinical and procedure outcomes after endoscopic ultrasonography-guided gastroenterostomy (EUS-GE) with a lumen-apposing metal stent (LAMS) in patients with malignant gastric outlet obstruction (GOO). Therefore, we compared clinical outcomes of EUS-GE for malignant GOO located in the stomach with obstruction located in the duodenum.PATIENTS AND METHODS: In this nationwide, multicenter, retrospective study, we included consecutive patients who underwent EUS-GE as palliative treatment for malignant GOO. Main outcomes were clinical success, serious adverse events (SAEs) recurrence of obstructive symptoms, and LAMS dysfunction.RESULTS: Between 2018 and 2023, 298 patients underwent EUS-GE. Clinical success was achieved in 73 of 82 patients with a gastric obstruction (94%) and in 174 of 216 patients with a duodenal obstruction (87%). No association was found between location of obstruction and clinical success (odds ratio [OR] 2.62, 95% confidence interval [CI] 0.91 to 7.52,
P = 0.073) or SAEs (OR 0.26, 95% CI 0.06 to 1.20,
P = 0.083). Recurrent obstructive symptoms occurred more frequently in patients with a gastric obstruction (hazard ratio 1.74, 95% CI 1.09 to 2.77,
P = 0.020). LAMS dysfunction did not differ between the groups (7 patients [9%] with a gastric obstruction and 11 patients [5%] with a duodenal obstruction).
CONCLUSIONS: In this study, EUS-GE in patients with a gastric obstruction had comparable technical and clinical efficacy and a similar safety profile to EUS-GE for duodenal obstruction. However, gastric obstruction was associated with recurrent symptoms of obstruction unrelated to LAMS dysfunction.
AB - BACKGROUND AND STUDY AIMS: It is currently unclear whether obstruction location affects clinical and procedure outcomes after endoscopic ultrasonography-guided gastroenterostomy (EUS-GE) with a lumen-apposing metal stent (LAMS) in patients with malignant gastric outlet obstruction (GOO). Therefore, we compared clinical outcomes of EUS-GE for malignant GOO located in the stomach with obstruction located in the duodenum.PATIENTS AND METHODS: In this nationwide, multicenter, retrospective study, we included consecutive patients who underwent EUS-GE as palliative treatment for malignant GOO. Main outcomes were clinical success, serious adverse events (SAEs) recurrence of obstructive symptoms, and LAMS dysfunction.RESULTS: Between 2018 and 2023, 298 patients underwent EUS-GE. Clinical success was achieved in 73 of 82 patients with a gastric obstruction (94%) and in 174 of 216 patients with a duodenal obstruction (87%). No association was found between location of obstruction and clinical success (odds ratio [OR] 2.62, 95% confidence interval [CI] 0.91 to 7.52,
P = 0.073) or SAEs (OR 0.26, 95% CI 0.06 to 1.20,
P = 0.083). Recurrent obstructive symptoms occurred more frequently in patients with a gastric obstruction (hazard ratio 1.74, 95% CI 1.09 to 2.77,
P = 0.020). LAMS dysfunction did not differ between the groups (7 patients [9%] with a gastric obstruction and 11 patients [5%] with a duodenal obstruction).
CONCLUSIONS: In this study, EUS-GE in patients with a gastric obstruction had comparable technical and clinical efficacy and a similar safety profile to EUS-GE for duodenal obstruction. However, gastric obstruction was associated with recurrent symptoms of obstruction unrelated to LAMS dysfunction.
U2 - 10.1055/a-2760-4544
DO - 10.1055/a-2760-4544
M3 - Article
C2 - 41777341
SN - 2364-3722
VL - 14
JO - Endoscopy international open
JF - Endoscopy international open
M1 - a27604544
ER -